Falkeborn M, Lithell H, Persson I, Vessby B, Naessén T
Department of Public Health and Caring Sciences/Geriatrics, University of Uppsala, Uppsala, Sweden.
Climacteric. 2002 Sep;5(3):240-8.
To determine the influence of hormone replacement therapy on serum lipids and antioxidative factors associated with the risk of coronary heart disease.
The effect of a sequential estradiol-norethisterone acetate regimen or placebo on lipid metabolism, antioxidative variables and fatty acid composition in serum was measured during the peak-estrogen phase in a randomized, double-blind, placebo-controlled study of 42 healthy postmenopausal women for 3 months.
Active treatment significantly reduced lipoprotein(a) by 15% (p = 0.005, compared with placebo), low-density lipoprotein (LDL) cholesterol by 10% (p = 0.005) and the LDL cholesterol/high-density lipoprotein (HDL) cholesterol ratio by 11% (p = 0.016). Serum triglycerides increased by 21% (p = 0.045). No effect was observed on HDL cholesterol, on apolipoproteins apo A(1) or apo B, or on non-esterified fatty acids in serum. No treatment effect was seen in the proportions of monounsaturated and polyunsaturated fatty acids. The concentration of malondialdehyde in serum did not change with the estrogen-progestin treatment.
This sequential estrogen-progestin therapy has a beneficial effect on apolipoprotein(a) and LDL cholesterol, but no effect on non-esterified fatty acids or the level of lipid peroxidation products in serum.
确定激素替代疗法对血清脂质及与冠心病风险相关的抗氧化因子的影响。
在一项针对42名健康绝经后女性的随机、双盲、安慰剂对照研究中，于雌激素峰值期测量序贯雌二醇 - 醋酸炔诺酮方案或安慰剂对血清脂质代谢、抗氧化指标及脂肪酸组成的影响，为期3个月。
积极治疗使脂蛋白(a)显著降低15%（与安慰剂相比，p = 0.005），低密度脂蛋白（LDL）胆固醇降低10%（p = 0.005），LDL胆固醇/高密度脂蛋白（HDL）胆固醇比值降低11%（p = 0.016）。血清甘油三酯升高21%（p = 0.045）。未观察到对HDL胆固醇、载脂蛋白A(1)或载脂蛋白B以及血清中非酯化脂肪酸有影响。单不饱和脂肪酸和多不饱和脂肪酸的比例未出现治疗效果。血清中丙二醛的浓度在雌激素 - 孕激素治疗后未发生变化。
这种序贯雌激素 - 孕激素疗法对载脂蛋白(a)和LDL胆固醇有有益作用，但对血清中非酯化脂肪酸或脂质过氧化产物水平无影响。
